BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is without doubt one of the prime most undervalued biotech shares to purchase now. Analyst Joseph Schwartz from Leerink Companions reiterated a Purchase score on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 6, conserving the worth goal at $105.
A pharmaceutical plant manufacturing a proprietary artificial oral type of a C-type natriuretic peptide.
The analyst advised buyers that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has promising pipeline developments and has exhibited strong monetary efficiency. Its fiscal Q2 2025 gross sales of $825 million exceeded expectations, prompting an upward revision of the decrease finish of its full-year income steering.
In response to the analyst, these developments recommend strong demand, particularly for the corporate’s product Voxzogo, which additionally surpassed gross sales expectations.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for severe and life-threatening medical circumstances and uncommon ailments. The corporate’s product pipeline contains Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
Whereas we acknowledge the potential of BMRN as an funding, we consider sure AI shares supply better upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.
